Survodutide
Also known as: BI 456906
Survodutide is a dual GLP-1 / glucagon receptor agonist co-developed by Boehringer Ingelheim and Zealand Pharma. NOT FDA-approved; received FDA Breakthrough Therapy Designation in 2024 for non-cirrhotic MASH with moderate/advanced fibrosis. Phase 3 ongoing (SYNCHRONIZE in obesity/T2DM; LIVERAGE and LIVERAGE-Cirrhosis in MASH).
Who's worth your money for Survodutide
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (99) of 9 scored sellers
$45.49 · 10mg · 99.0% purity
Best value
Lowest $/mg among scored sellers
$84.00 · 12mg · 99.9% purity
Average price
$21.65/mg
Sellers
22
45-day trend
+36.4%
13 of 22 sellers have a current price· 1 stale hidden· 3 unverified hidden
Top Merit pick
🇺🇸 Glacier Aminos99✓ verified at source · 1h ago
$4.55/mg -79% vs avg$45.49
10mg
- 🇺🇸 Profound Aminos95
via Disclosed Labs · 1h ago
$7.00/mg -67.7% vs avg$84.00
12mg
- 🇺🇸 Orbitrex Peptides95
via Disclosed Labs · 1h ago
$10.00/mg -53.8% vs avg$99.99
10mg
no purityBuy Code Orbitrex10 · 10% off - 🇺🇸 Polaris Peptides90
via Disclosed Labs · 1h ago
$15.00/mg -30.7% vs avg$75.00
5mg
no purity - 🇺🇸 Ruo Bio88
✓ verified at source · 1h ago
$9.80/mg -54.7% vs avg$98.00
10mg
- optimasupply.is86
via Disclosed Labs · 1h ago
$16.67/mg -23% vs avg$100
6mg
- 🇺🇸 EZ Peptides85
✓ verified at source · 1h ago
$7.80/mg -64% vs avg$78.00
10mg
- True Peptide82
via Disclosed Labs · 1h ago
$12.00/mg -44.6% vs avg$120
10mg
- 🇭🇰 zztai Peptide Ltd42
✓ verified at source · 1h ago
$25.70/mg +18.7% vs avg$257
10mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Survodutide
Get one email when the market actually moves — no newsletter, no noise.
About Survodutide
CAS
2805997-46-8
Molecular formula
C192H289N47O61
Typical dose range
0.3–2.7 mg once weekly subcutaneous (clinical trials; Phase II/III dose-escalation)
Half-life
~6 days
COAs for Survodutide
27 third-party tests across 10 vendors. Each card links to the full report.
For
Survodutide
by Glacier Aminos· batch SUR10GA-01
For
Survodutide
by Profound Aminos· batch Yellow Cap
For
Survodutide
by Real Peptides· batch Clear Cap/Purple Crimp
For
Suvrodutide
by Kimera Chems· batch KC-SVD-BLK1
For
Survodutide
by True Peptide· batch SURV-099-TPL
For
Survodutide
by Skye Peptides· batch SV25-12-001
For
Survodutide
by Ruo Bio· batch sur001
For
Survodutide
by Kimera Chems· batch KC-SVD-RED1
For
Survodutide
by Certified Peptides· batch SURVO10102125
For
Survodutide
by Skye Peptides· batch SV25-06-001
For
Survodutide
by EZ Peptides· batch EZP-SURV1009082025-01
For
Survodutide
by EZ Peptides· batch EZP-SURV1009082025-01
For
Survodutide
by Profound Aminos· batch 2025-01-23
For
Survodutide
by Hydro Research Peptides· batch 2024-08-05
For
Survodutide
by Optima Supply· batch 2024-08-05
For
Survodutide
by Hydro Research Peptides· batch Survodutide-6028
For
Survodutide
by Optima Supply· batch Survodutide-6033
For
Survodutide
by Peptidology· batch 1671
For
Suvrodutide
by Kimera Chems· batch KC-SVD-RED1
Purity not on file
For
Survodutide
by Skye Peptides· batch SV25-12-001
Purity not on file
For
Survodutide
by Skye Peptides· batch SV25-12-001
Purity not on file
For
Survodutide
by Skye Peptides· batch SV25-06-001
Purity not on file
For
Survodutide
by Skye Peptides· batch SV25-06-001
Purity not on file
For
Survodutide
by Hydro Research Peptides· batch Survodutide-6028
20 citations indexed for Survodutide
animal · 2026
Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease
Aims Survodutide is a novel long-acting dual glucagon (GCGR)/glucagon-like peptide-1 (GLP-1R) receptor agonist currently in phase-3 clinical development for the treatment of people living with obesity and metabolic dysfunction-associated steatohepatitis.
Study · 2026
Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties
Survodutide (BI 456906) is an investigational once-weekly dual glucagon and Glucagon-like Peptide (GLP-1) receptor agonist being developed for obesity.
Study · 2026
Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes
Background For persons living with both type 2 diabetes and obesity, weight management may be the most effective therapy for type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor agonists have potent weight-reducing effects, and other mechanisms may confer additional benefits.
Study · 2026
Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN)
Introduction We aimed to describe the rationale, design, and overall baseline characteristics of the trial evaluating the efficacy, safety, and tolerability of survodutide in Chinese adults with overweight or obesity (SYNCHRONIZE™-CN, NCT06214741).
rct · 2026
Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity
Aims This post hoc analysis evaluated the effect of survodutide on beta-cell function, insulin sensitivity, and glucose biomarkers in two phase 2 trial populations.
review · 2026
Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis
Recent therapeutic advances have resulted in US Food and Drug Administration (FDA) approval of the first pharmacological agents-resmetirom and semaglutide-for advanced metabolic dysfunction-associated steatohepatitis (MASH) without cirrhosis, reshaping the therapeutic landscape of the disease.